JP2009517343A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517343A5
JP2009517343A5 JP2008540240A JP2008540240A JP2009517343A5 JP 2009517343 A5 JP2009517343 A5 JP 2009517343A5 JP 2008540240 A JP2008540240 A JP 2008540240A JP 2008540240 A JP2008540240 A JP 2008540240A JP 2009517343 A5 JP2009517343 A5 JP 2009517343A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
scf
vector
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008540240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/043937 external-priority patent/WO2007059010A2/en
Publication of JP2009517343A publication Critical patent/JP2009517343A/ja
Publication of JP2009517343A5 publication Critical patent/JP2009517343A5/ja
Pending legal-status Critical Current

Links

JP2008540240A 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法 Pending JP2009517343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73705805P 2005-11-14 2005-11-14
PCT/US2006/043937 WO2007059010A2 (en) 2005-11-14 2006-11-13 Stem cell factor therapy for tissue injury

Publications (2)

Publication Number Publication Date
JP2009517343A JP2009517343A (ja) 2009-04-30
JP2009517343A5 true JP2009517343A5 (https=) 2010-01-07

Family

ID=38049189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540240A Pending JP2009517343A (ja) 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法

Country Status (7)

Country Link
US (1) US8404653B2 (https=)
EP (1) EP1948246B1 (https=)
JP (1) JP2009517343A (https=)
CN (1) CN101563097A (https=)
AU (1) AU2006315601A1 (https=)
CA (1) CA2629775A1 (https=)
WO (1) WO2007059010A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
JP5467742B2 (ja) * 2007-08-24 2014-04-09 国立大学法人 岡山大学 Ｅｃｐを有効成分とする左室リモデリングの予防及び治療剤。
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
GB201400562D0 (en) 2014-01-14 2014-03-05 Orla Protein Technologies Ltd Protein coated polymeric substrate
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2019200240A1 (en) * 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-scf) lipid nanocarriers and methods of use thereof
JP2022526187A (ja) * 2019-04-12 2022-05-23 エモリー ユニバーシティー 造血細胞の細胞傷害性を促進するための組成物及び方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
US6326198B1 (en) * 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5827216A (en) * 1995-06-07 1998-10-27 Cormedics Corp. Method and apparatus for accessing the pericardial space
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2213906A1 (en) 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6258119B1 (en) 1996-11-07 2001-07-10 Myocardial Stents, Inc. Implant device for trans myocardial revascularization
US5931810A (en) * 1996-12-05 1999-08-03 Comedicus Incorporated Method for accessing the pericardial space
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
DE69837491T2 (de) * 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. Menschliche mesenchymale stammzellen aus peripherem blut
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6251418B1 (en) 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US7078387B1 (en) * 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
WO2002030443A2 (en) 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
EP1379197A4 (en) * 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US7605128B2 (en) * 2002-02-14 2009-10-20 Buck Institute For Age Research Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
US20070238675A1 (en) * 2003-08-11 2007-10-11 Phillips M I Stem Cell Beacon
WO2005053729A1 (en) 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Similar Documents

Publication Publication Date Title
Rufaihah et al. Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel
CN104884076B (zh) 利用了hmgb1片段的心肌梗塞的治疗方法
WO2006121532A3 (en) Treatment for heart disease
JP2009517343A5 (https=)
JP2009545310A5 (https=)
US7125856B1 (en) Angiogenic growth factors for treatment of peripheral neuropathy
WO2004019921A3 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
WO2002064757A3 (en) Influenza viruses with enhanced transcriptional and replicational capacities
CN103800045A (zh) 一种医疗用心脏填塞物
CA2354029A1 (en) Gene therapy for cardiomyopathy
JP2020510628A5 (https=)
JP2019521976A5 (https=)
JP2023105066A (ja) 組織治癒剤
Fidelis-de-Oliveira et al. Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts
AU782819B2 (en) Angiogenic growth factors for treatment of peripheral neuropathy
JP2011522875A (ja) 電気的除細動を予防するためのドロネダロン
ES2566344T3 (es) VEGF-A para inducir regeneración del tejido miocárdico
Nie et al. Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model
Brooks et al. Takotsubo syndrome after surgical and nonsurgical oral and maxillofacial events: review of published cases
JP2012524781A5 (https=)
JP2008540536A5 (https=)
Stamm et al. Cardiac cell therapy: a realistic concept for elderly patients?
Ruiz-Garcia et al. Cardiac shock-wave therapy in the treatment of refractive angina pectoris
US20230364267A1 (en) Pre-clinical modified rna approaches used in large animals for muscle and vascular regeneration
Sanganalmath et al. The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up